Immunomic Therapeutics and BioBuzz Maryland to Celebrate Advancement of the Investigational LAMP-Vax Technology

ROCKVILLE, Md.--()--Immunomic Therapeutics, Inc. (ITI) announced today that they will celebrate the company’s recent pivot to oncology application with their investigational LAMP-Vax™ technology tomorrow. The event is jointly hosted with BioBuzz Maryland and provides biotech professionals with the opportunity to network and learn more about Immunomic’s DNA vaccine technology and the company’s research in glioblastoma (GBM).

Who: Immunomic Therapeutics, Inc. (ITI) and BioBuzz Maryland

What: Networking event to celebrate oncology research advancements with Immunomic’s LAMP-Vax technology

When: Thursday, July 27, 2017, 5:00 p.m. EDT

Where: Bar Louie, 150 Gibbs Street, Rockville, MD 20850

About LAMP-Vax

ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and LAMP Technology, visit

About BioBuzz

Since 2010 BioBuzz has been hosting the Maryland Biotech community at monthly networking events and social gatherings. What makes these events so unique is the causal, social atmosphere and the diverse group of biotech professionals who attend. There are no lectures or seminars and there’s no agenda or program; just fun and networking with your peers. BioBuzz is working to build a stronger community by bringing the biotech workforce out of the labs to culture relationships, instead of cells. By building a stronger social community we will enhance business and job opportunities for everyone in the region.


Immunomic Therapeutics, Inc.
Sia Anagnostou, 717-327-1822

Release Summary

Immunomic Therapeutics, Inc. to celebrate the company’s recent pivot to oncology application with their investigational LAMP-Vax technology.


Immunomic Therapeutics, Inc.
Sia Anagnostou, 717-327-1822